All Stories

  1. Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration
  2. Antimigratory and Antiproliferative Effects of the Brain‐Targeted Peptide Conjugate PepH3‐vCPP2319 on Triple Negative Breast Cancer Cell Cultures
  3. PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier
  4. The Potential of Peptide-Based Inhibitors in Disrupting Protein–Protein Interactions for Targeted Cancer Therapy
  5. Optimizing magnetic hyperthermia for melanoma: the role of nanoparticle uptake inhibition
  6. vCPP2319 interacts with metastatic breast cancer extracellular vesicles (EVs) and transposes a human blood-brain barrier model
  7. Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation
  8. The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis
  9. Non-toxicity of Plant Candicidal Peptides for Mammalian Cell Lines and Galleria mellonella Model to Improving Selectivity for Clinical Use
  10. Quantitative Imaging of the Action of vCPP2319, an Antimicrobial Peptide from a Viral Scaffold, against Staphylococcus aureus Biofilms of a Clinical Isolate
  11. Panobinostat-loaded folate targeted liposomes as a promising drug delivery system for treatment of canine B-cell lymphoma
  12. Biological response and cell death signaling pathways modulated by tetrahydroisoquinoline-based aldoximes in human cells
  13. Structural and Biochemical Characterization of Three Antimicrobial Peptides from Capsicum annuum L. var. annuum Leaves for Anti-Candida Use
  14. Rabbit derived VL single-domains as promising scaffolds to generate antibody–drug conjugates
  15. Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors
  16. Posters
  17. Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide–Porphyrin Conjugates
  18. The Use of Antibody-Antibiotic Conjugates to Fight Bacterial Infections
  19. The antimetastatic breast cancer activity of the viral protein‐derived peptide vCPP2319 as revealed by cellular biomechanics
  20. Development of Breast Cancer Spheroids to Evaluate Cytotoxic Response to an Anticancer Peptide
  21. Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening
  22. Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules
  23. Penetrating the Blood-Brain Barrier with New Peptide–Porphyrin Conjugates Having anti-HIV Activity
  24. Orally Active Peptide Vector Allows Using Cannabis to Fight Pain While Avoiding Side Effects
  25. Estimating peptide half‐life in serum from tunable, sequence‐related physicochemical properties
  26. Bioconjugate Supramolecular Pd2+ Metallacages Penetrate the Blood Brain Barrier In Vitro and In Vivo
  27. The Challenge of Peptide Proteolytic Stability Studies: Scarce Data, Difficult Readability, and the Need for Harmonization
  28. The Challenge of Peptide Proteolytic Stability Studies: Scarce Data, Difficult Readability, and the Need for Harmonization
  29. To What Extent Do Fluorophores Bias the Biological Activity of Peptides? A Practical Approach Using Membrane-Active Peptides as Models
  30. DPepH3, an Improved Peptide Shuttle for Receptor-independent Transport Across the Blood-Brain Barrier
  31. The Effect of Different Fluorophores on Fluorescence-Based Techniques
  32. Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?
  33. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition
  34. P545 Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition
  35. Biologically active peptides linked to antibody fragments
  36. Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims
  37. SAT0046 TNF antagonist drug safety assessment by pharmacovigilance signaling and post-marketing adverse event reports
  38. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles
  39. Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies